Amgen, Inc. (NASDAQ:AMGN) announced that it will hold a post-American Society of Clinical Oncology (ASCO) summary webcast on Tuesday, June 3, 2014, at 1 p.m. PT. Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen’s clinical development team, will participate to discuss data presented at ASCO and Amgen’s broader oncology portfolio of products. Amgen, Inc. (NASDAQ:AMGN) net profit margin is 24.90% and weekly performance is 2.21%. On last trading day company shares ended up $116.00. Analysts mean target price for the company is $132.78. Amgen, Inc. (NASDAQ:AMGN) distance from 50-day simple moving average (SMA50) is 0.08%.
Japan’s largest pharmaceutical company, Takeda, recently signed an agreement with Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) to commercialize the Israeli company’s innovative treatment for Parkinson’s disease, rasagiline, in Japan. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) shares fell -0.51% in last trading session and ended the day on $50.66. TEVA gross Margin is 53.00% and its return on assets is 2.90%.Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) quarterly performance is 3.49%.
Shares of Celgene Corp. (NASDAQ:CELG) are down -0.84% after J.P. Morgan (JPM) downgraded the stock to “neutral” from “overweight” and lowered its price target to $170. from $180. Celgene Corporation (NASDAQ:CELG) shares moved down -0.67% in last trading session and was closed at $153.26, while trading in range of $151.24 – $153.55. Celgene Corporation (NASDAQ:CELG) year to date (YTD) performance is -9.30%.
Bristol-Myers Squibb Co (NYSE:BMY) announced two separate agreements related to its immuno-oncology research—a collaboration with CytomX to develop probodies and a clinical-trial collaboration with Incyte to evaluate a combination regimen of two inhibitors. The worldwide research collaboration and license agreement between Bristol-Myers Squibb and CytomX Therapeutics aims to discover, develop, and commercialize novel therapies against multiple immuno-oncology targets using CytomX’s proprietary Probody Platform of monoclonal antibodies that remain inert in healthy tissue but are activated specifically in the cancer microenvironment. Bristol-Myers Squibb Co (NYSE:BMY) ended the last trading day at $49.52. Company weekly volatility is calculated as 1.33% and price to cash ratio as 11.63.Bristol-Myers Squibb Co (NYSE:BMY) showed a positive weekly performance of 1.66%.
Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) announced on 20 may the establishment of a strategic alliance with Pathology, Inc. in Torrance, Calif., that designates the company as a Roche Molecular Center of Excellence (MCOE) for the next five years. On last trading day company shares ended up $37.12.